Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Cell. 2016 Dec 15;167(7):1719–1733.e12. doi: 10.1016/j.cell.2016.11.052

Figure 4. Extension of Lifespan and Prevention of Age-Associated Phenotypes by In Vivo Induction of Oct4, Sox2, Klf4, and c-Myc.

Figure 4

(A) Body weight of LAKI and LAKI 4F mice upon cyclic doxycycline administration. LAKI (−Dox n = 20; +Dox n = 13) and LAKI 4F (−Dox n = 18; +Dox n = 15).

(B) Survival of LAKI and LAKI 4F mice upon cyclic doxycycline administration. LAKI (−Dox n = 20; +Dox n = 13) and LAKI 4F (−Dox n = 18; +Dox n = 15). ****p < 0.0001 according to log-rank (Mantel-Cox) test.

(C) Representative photograph of 16-week-old LAKI 4F mice upon cyclic doxycycline administration.

(D) Necropsy analysis of 14-week-old LAKI 4F mice upon cyclic doxycycline administration.

(E) Histological analysis of indicated organs of 14-week-old LAKI 4F mice upon cyclic doxycycline administration. Arrows depict decreased epidermal thickness and increased keratinization, small lymphoid nodules in the splenic white pulp, tubular atrophy in the kidney, and loss of parietal cells in the stomach of untreated LAKI 4F mice. Scale bar, 50 μm (skin and kidney) and 100 μm (spleen and stomach). *p < 0.05, ***p < 0.001, and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.

(F) Histology of aortic arch of LAKI 4F mice upon cyclic doxycycline administration. Scale bar, 50 μm. *p < 0.05 and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.

(G) ECG analysis in LAKI 4F mice upon cyclic doxycycline administration (−Dox n = 4; +Dox n = 4). Heart rate represented as beats per minute (bpm). *p < 0.05, **p < 0.001, and ****p < 0.0001 according to one-way ANOVA with Bonferroni correction.

Data are presented as mean ± SEM. See also Figure S4.